BACKGROUND: Data regarding the patterns and the mechanisms of deregulation of the insulin growth factor (IGF) pathway in adult and paediatric gastrointestinal stromal tumours (GISTs) are limited. METHODS: We investigated the expression profiling of the genes encoding the main components of the IGF signalling pathway in 131 GISTs (106 adults, 21 paediatric and four young adults) and 25 other soft-tissue sarcomas (STS) using an Affymetrix U133A platform. IGF2 was investigated for loss of imprinting (LOI) whereas IGF1R was analysed for copy number aberration and mutation. RESULTS: IGF2 was the most highly overexpressed gene of the IGF pathway in GIST. IGF2 expression was also significantly higher than in other STS. IGF2 expression was correlated to the age onset and mutational status of GIST. Indeed, IGF2 expression was significantly higher in the 'adult' group than in the 'paediatric' and 'young adult' groups. Among adult GIST, IGF2 expression was higher in tumours lacking Homo sapiens v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) or alpha-type platelet-derived growth factor receptor (PDGFRA) mutations in comparison with mutated cases. A trend for a higher expression of IGF2 in resistant GIST in comparison to responsive GIST was also found. Overexpression of IGF2 was not related to LOI. Conversely, the expression of the IGF1R gene was significantly higher in the paediatric group than in the adult group. No copy number gains or mutations of IGF1R were observed. CONCLUSION: The IGF pathway is deregulated in GIST with distinct patterns according to age onset and mutational status. The IGF pathway may represent a therapeutic target in patients with primary or secondary resistance to imatinib.
BACKGROUND: Data regarding the patterns and the mechanisms of deregulation of the insulin growth factor (IGF) pathway in adult and paediatric gastrointestinal stromal tumours (GISTs) are limited. METHODS: We investigated the expression profiling of the genes encoding the main components of the IGF signalling pathway in 131 GISTs (106 adults, 21 paediatric and four young adults) and 25 other soft-tissue sarcomas (STS) using an Affymetrix U133A platform. IGF2 was investigated for loss of imprinting (LOI) whereas IGF1R was analysed for copy number aberration and mutation. RESULTS:IGF2 was the most highly overexpressed gene of the IGF pathway in GIST. IGF2 expression was also significantly higher than in other STS. IGF2 expression was correlated to the age onset and mutational status of GIST. Indeed, IGF2 expression was significantly higher in the 'adult' group than in the 'paediatric' and 'young adult' groups. Among adult GIST, IGF2 expression was higher in tumours lacking Homo sapiens v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) or alpha-type platelet-derived growth factor receptor (PDGFRA) mutations in comparison with mutated cases. A trend for a higher expression of IGF2 in resistant GIST in comparison to responsive GIST was also found. Overexpression of IGF2 was not related to LOI. Conversely, the expression of the IGF1R gene was significantly higher in the paediatric group than in the adult group. No copy number gains or mutations of IGF1R were observed. CONCLUSION: The IGF pathway is deregulated in GIST with distinct patterns according to age onset and mutational status. The IGF pathway may represent a therapeutic target in patients with primary or secondary resistance to imatinib.
Authors: Paul Hamberg; Floris A de Jong; Joke G Boonstra; Jaap van Doorn; Jaap Verweij; Stefan Sleijfer Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: N Sueoka; H Y Lee; S Wiehle; R J Cristiano; B Fang; L Ji; J A Roth; W K Hong; P Cohen; J M Kurie Journal: Oncogene Date: 2000-09-07 Impact factor: 9.867
Authors: B Liegl; I Kepten; C Le; M Zhu; G D Demetri; M C Heinrich; C D M Fletcher; C L Corless; J A Fletcher Journal: J Pathol Date: 2008-09 Impact factor: 7.996
Authors: Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher Journal: Science Date: 2003-01-09 Impact factor: 47.728
Authors: Guillermo A Escobar; William A Robinson; Trevor L Nydam; Drew C Heiple; Glen J Weiss; Linda Buckley; Rene Gonzalez; Martin D McCarter Journal: BMC Cancer Date: 2007-01-17 Impact factor: 4.430
Authors: Carol Beadling; Janice Patterson; Emily Justusson; Dylan Nelson; Maria A Pantaleo; Jason L Hornick; Matias Chacón; Christopher L Corless; Michael C Heinrich Journal: Cancer Med Date: 2013-02-03 Impact factor: 4.452
Authors: David S Moura; Rafael Ramos; Antonio Fernandez-Serra; Teresa Serrano; Julia Cruz; Ramiro Alvarez-Alegret; Rosa Ortiz-Duran; Luis Vicioso; Maria Luisa Gomez-Dorronsoro; Xavier Garcia Del Muro; Javier Martinez-Trufero; Jordi Rubio-Casadevall; Isabel Sevilla; Nuria Lainez; Antonio Gutierrez; Cesar Serrano; Maria Lopez-Alvarez; Nadia Hindi; Miguel Taron; José Antonio López-Guerrero; Javier Martin-Broto Journal: Oncotarget Date: 2018-04-03